跳至主要内容
临床试验/EUCTR2020-005772-35-BE
EUCTR2020-005772-35-BE进行中(未招募)1 期

Study on linezolid use and adverse drug reactions in clinical practice: Follow-up of patients treated in Belgian Hospitals - LINEZOLID

CLouvain0 个研究点目标入组 120 人开始时间: 2021年2月9日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adult patients (> 18 years)
  • Treated with linezolid for a period > 3 days
  • Hospitalizated or non-hospitalizated patients
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 90
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • Patients with abnormal blood count at the beginning of the treatment (platelets level < 75, 000/mm3 and/or hemoglobin < 8 g/dl)

研究者

发起方
CLouvain

相似试验

已完成
1 期
Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)Multi-Drug Resistant TuberculosisExtensively Drug Resistant Tuberculosis
NCT00691392Centers for Disease Control and Prevention26
尚未招募
4 期
pharmacokinetics and toxicity of linezolid in MDR-TB patientstuberculosis MDR-TB10028440
NL-OMON29905niversitair Medisch Centrum Groningen10
进行中(未招募)
不适用
Investigation of the blood levels of selected antibiotics in critically ill patients undergoing dialysisSepsis and acute renal failure (ARF) are pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated and may result in either underdosing, causing treatment failure and antibiotic resistance, or overdosing resulting in drug toxicity. The aim of this study is to collect pharmacokinetic data for evaluating underdosing or overdosing of linezolid and meropenem in patients receiving renal replacement therapy.
EUCTR2013-000899-16-DEDepartment of Pharmacy Unversitätsmedizin Mainz
已完成
4 期
Linezolid for Treatment of Nontuberculous Mycobacterial DiseasesNon-tuberculous Mycobacterial Infections
NCT03220074Mahidol University40
尚未招募
2 期
To observe if administration of drug namely linezolid along with standard four drug regimen in intensive(initial) phase of Tubercular meningitis will help reduce death and disability among patients when compared to standard four drugAntitubercular drug therapy alone.
CTRI/2019/06/019501Aiims